Categories

Social norms often view #ViolenceAgainstWomen 🙅🏾‍♀‍🙅‍♀‍🙅🏿‍♀‍🙅🏿‍♀‍🙅🏾‍♀‍ as a ‘private matter’ discouraging survivors from seeking help. Violence IS preventable! 👉🏽 paho.org/en/campaigns/i…

Social norms often view #ViolenceAgainstWomen 🙅🏾‍♀‍🙅‍♀‍🙅🏿‍♀‍🙅🏿‍♀‍🙅🏾‍♀‍ as a ‘private matter’ discouraging survivors from seeking help.

Violence IS preventable!

👉🏽 paho.org/en/campaigns/i…

#OrangeTheWorld
#16Days
#EndVAWNow https://t.co/dc0BHaViB6

 
Categories

August 7, 2019 UPDATE: Treatment of Peripheral Arterial Disease with Paclitaxel-Coated Balloons and Paclitaxel-Eluting Stents Potentially Associated with Increased Mortality

The FDA is providing updated information about a late mortality signal in patients treated for peripheral artery disease (PAD) in the femoropopliteal artery with paclitaxel-coated balloons and paclitaxel-eluting stents. This communication updates the January 17 and March 15, 2019 notifications.

http://www.fda.gov/medical-devices/letters-health-care-providers/august-7-2019-update-treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel

 
Categories

Sandoz, Inc. Issues Nationwide Recall of One Lot of Enoxaparin Sodium Injection, USP 40mg/0.4 mL Due to Temperature Excursion During Shipping

Princeton, NJ, Sandoz Inc. (“Sandoz”) is initiating a recall of one lot (SAB06761A, Exp 04/2023) of Enoxaparin Sodium Injection, USP 40 mg/0.4 mL Single-Dose Syringes to the consumer level. A portion of lot SAB06761A experienced a temperature excursion during shipment. Enoxaparin Sodium for Injectio

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-nationwide-recall-one-lot-enoxaparin-sodium-injection-usp-40mg04-ml-due